BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30407350)

  • 1. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
    Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
    Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G; Schmidt L; Tolat P; Riese M; Kilari D
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab.
    Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.
    Milowsky MI; Rosmarin A; Tickoo SK; Papanicolaou N; Nanus DM
    Cancer; 2002 Jan; 94(1):111-6. PubMed ID: 11815966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].
    Kullmann T; Pintér T; Szepesvári Z; Kránitz N; Culine S
    Orv Hetil; 2016 Mar; 157(11):436-9. PubMed ID: 26947093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
    Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
    Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
    Mizutani K; Horie K; Nagai S; Tsuchiya T; Saigo C; Kobayashi K; Miyazaki T; Deguchi T
    Mol Clin Oncol; 2017 Dec; 7(6):988-990. PubMed ID: 29285361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
    Staehler M; Haseke N; Schöppler G; Stadler T; Karl A; Siebels M; Ihrler S; Stief CG
    Eur J Med Res; 2008 Nov; 13(11):531-5. PubMed ID: 19073390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A renal cancer with intermediate characteristics between collecting (Bellini) duct carcinoma and urothelial carcinoma: case report and review of the literature.
    Maestroni U; Ferretti S; Dinale F; Froio E; Pilato FP; Ciuffreda M; Mellissari M; Cortellini P
    Tumori; 2006; 92(6):545-8. PubMed ID: 17260499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
    Staehler M; Schöppler G; Haseke N; Stadler T; Karl A; Siebels M; Ihrler S; Stief CG
    Clin Genitourin Cancer; 2009 Jan; 7(1):58-61. PubMed ID: 19213670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
    Zhao RN; Nie LH; Gong R; Wang JZ; Wazir R; Liu LR; Song TR; Wei Q
    Int Urol Nephrol; 2013 Aug; 45(4):1017-21. PubMed ID: 23686671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Complete Remission of Metastatic Renal Cell Carcinoma with Invasion of the Duodenum and Pancreas after Treatment with Nivolumab Plus Ipilimumab Followed by Axitinib and Surgery : A Case Report].
    Hagimoto H; Yamazaki T; Kashima S; Yoshino T; Goto T; Sano T; Sawada A; Akamatsu S; Kobayashi T; Nakano K; Yagi S; Matsuoka Y; Fujimoto M; Kitamura T; Ogawa O
    Hinyokika Kiyo; 2021 May; 67(5):197-203. PubMed ID: 34126663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
    Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
    J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
    Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
    Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
    Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
    Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
    Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
    Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.